These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


196 related items for PubMed ID: 3134383

  • 1. Focus on fenofibrate.
    Brown WV.
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():31-40. PubMed ID: 3134383
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
    Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, Sniderman AD, Tan MH, Tremblay G, Sorisky A, Shurzinske L, Black DM.
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV.
    Am J Med; 1987 Nov 27; 83(5B):85-9. PubMed ID: 3688012
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
    Sirtori CR, Montanari G, Gianfranceschi G, Sirtori M, Galli G, Bosisio E.
    Eur J Clin Pharmacol; 1985 Nov 27; 28(6):619-24. PubMed ID: 3840743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M, Bortolini M, Salko T, Freudenreich MO, Isaacsohn JL, Troendle AJ, Gonasun L.
    Am J Cardiol; 2003 Jan 15; 91(2):238-40. PubMed ID: 12521642
    [No Abstract] [Full Text] [Related]

  • 17. Choosing the right lipid-regulating agent. A guide to selection.
    Farmer JA, Gotto AM.
    Drugs; 1996 Nov 15; 52(5):649-61. PubMed ID: 9118815
    [Abstract] [Full Text] [Related]

  • 18. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
    Leiss O, Meyer-Krahmer K, von Bergmann K.
    J Lipid Res; 1986 Jul 15; 27(7):713-23. PubMed ID: 3760707
    [Abstract] [Full Text] [Related]

  • 19. Spectral-Domain OCT Imaging of Lipemia Retinalis.
    Teoh CS, Yuen YS.
    Ophthalmol Retina; 2021 Oct 15; 5(10):1016. PubMed ID: 34579870
    [No Abstract] [Full Text] [Related]

  • 20. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.
    Am J Cardiol; 2001 Jan 01; 87(1):44-8. PubMed ID: 11137832
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.